Felix Chu

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

F. Michael Yakes, Jason Chen, Jenny Tan et al. · Molecular Cancer Therapeutics · 2011 · 1.3K citations · Full text

Angiogenesis, Novel Met, Medicine +13

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

Joseph P. Eder, Geoffrey I. Shapiro, Leonard J. Appleman et al. · Clinical Cancer Research · 2010 · 191 citations · Full text

<i>In Vitro</i> and <i>In Vivo</i> Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

Frauke Bentzien, Marcus Zuzow, Nathan Heald et al. · Thyroid · 2013 · 129 citations · Full text

Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens

Jeff DeFalco, Michael Harbell, Amy Manning-Bog et al. · Clinical Immunology · 2017 · 117 citations · Full text

Immunology, Immunoediting, Immunotherapy +16

Pulmonary edema and acute upper airway obstruction

Thomas A. Tami, Felix Chu, Thomas O. Wildes et al. · The Laryngoscope · 1986 · 110 citations